A Phase 1 interventional study of RBD7022 and RBD7022 in Hyperlipemia, sponsored by Suzhou Ribo Life Science Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-01.
Sponsored by Suzhou Ribo Life Science Co. Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Hyperlipidemias with a site in China — 30 open to participants now, 37 under way, 7 of them phase 3. Hyperlipidemias · China.
Among the 94 studies in Hyperlipidemias with a site in China, this one is the 55th largest by enrollment of the 78 interventional ones that give a count, is one of 10 that started in 2023, is one of 19 in phase 1, and was the 50th registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →30 of the 94 studies in Hyperlipidemias with a site in China are open now. Recruiting first, the newest first:
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–79
Jianyin Zhou · Sites in China
Ages 18–65
Beijing Suncadia Pharmaceuticals Co., Ltd · Sites in China
Ages 18+
Shanghai 10th People's Hospital · Sites in China
Ages 18–60
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 12 · Phase 3 20 · Phase 4 7
First in 2005; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is close to the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 155 across the 78 interventional studies, 1,151 across the 16 observational. Of the 44 that completed or were terminated, 4 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 94 have an industry lead sponsor. The 10 most frequent:
This study is registered under Suzhou Ribo Life Science Co. Ltd., one of the names counted as Suzhou Ribo Life Science Co., Ltd.. Under that name alone:
Suzhou Ribo Life Science Co. Ltd. is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Suzhou Ribo Life Science Co., Ltd. has 1 study filed under Hyperlipidemias — fewer than ten, so there is no comparison to draw.
10 of the studies in Hyperlipidemias with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-02-11 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07230730Phase 3Beijing Suncadia Pharmaceuticals Co., LtdA Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia | 2027-10 |
| NCT05457582Nanjing First Hospital, Nanjing Medical UniversityPCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI | 2026-12-30 |
| NCT07938099Xin LiReal-World Study Comparing PCSK9 Monoclonal Antibody With Cholesterol Absorption Inhibitors in Patients With ASCVD for Secondary Prevention | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 94 studies in Hyperlipidemias with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, single blind, placebo controlled, single center phase I study to evaluate the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamics of single and multiple ascending doses of subcutaneously administered RBD7022 in participants with normal or elevated LDL-c cholesterol. The study will be performed in 2 phases: single ascending dose (SAD) phase and multiple ascending doses (MAD) phase in participants. The decision to escalate to subsequent dose levels will be made by the SRC based on the review of all available safety information in each cohort.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in SAD experimental groups will receive a single subcutaneous injection of RBD7022 on Day 0.
Drug: RBD7022
Subjects in MAD experimental groups will receive one subcutaneous injection of RBD7022 on Day 0 and another subcutaneous injection of RBD7022 on Day 28.
Drug: RBD7022
Subjects in SAD placebo groups will receive a single subcutaneous injection of placebo on Day 0.
Drug: Placebo
Subjects in MAD placebo groups will receive one subcutaneous injection of placebo on Day 0 and another subcutaneous injection of placebo on Day 28 .
Drug: Placebo
Subcutaneously Administered RBD7022 in Healthy Subjects.
Subcutaneously Administered RBD7022 in Healthy Subjects.
Subcutaneously Administered Placebo in Healthys Subject.
Subcutaneously Administered Placebo in Healthys Subject.
Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0
By the examination of vital signs, physical examination, 12-lead electrocardiogram (ECG), and laboratory examination, the investigator will make an assessment of intensity for each AE and SAE reported during the study according to CTCAE V5.0
Time frame: SAD up to Day 180; MAD up to Day 208
The serum LDL-C level after subject dosing RBD7022
measure the LDL-C level in blood by lab examination and eveluate the effect of RBD7022 on Circulating LDL-c Levels (Determination of % Lowering of LDL-c to treatment/Baseline LDL-c Level)
Time frame: SAD up to Day 180; MAD up to Day 208
The serum PCSK9 level after subject dosing RBD7022
measure the pcsk9 level in blood by lab examination and eveluate the effect of RBD7022 on Circulating PCSK9 Levels (Determination of % Lowering of PCSK9 to treatment/Baseline PCSK9 Level).
Time frame: SAD up to Day 180; MAD up to Day 208
Other blood lipoprotein and lipid parameters besides LDL-c
measure other blood lipoprotein and lipid parameters besides LDL-c in blood by lab examination and eveluate % change and absolute change in other lipoprotein and lipid parameters(TC、TG、Lp (a)、HDL-C、non HDL-C、Apo B、Apo A1、Apo A 1/ Apo B ratio) from baseline up to Day 208
Time frame: SAD up to Day 180; MAD up to Day 208
The effect of RBD7022 monotherapy or RBD7022 combination with statin in patients with elevated LDL-C
measure the LDL-C and pcsk9 level in blood by lab examination and assess % change and absolute change in LDL-c and PCSK9 from baseline up to Day 208
Time frame: SAD up to Day 180; MAD up to Day 208
To characterize the pharmacokinetic parameter Cmax
Plasma Maximum concentration (Cmax)
Time frame: SAD: within 60 min before dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24, 48 and 72 hours after dosing; MAD: within 60 minutes before day 0 and day 28 dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24 ,48 and 72 hours after Day 0 and day 28 dosing
To characterize the pharmacokinetic parameter Tmax
Time to maximum concentration (Tmax)
Time frame: SAD: within 60 min before dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24, 48 and 72 hours after dosing; MAD: within 60 minutes before day 0 and day 28 dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24 ,48 and 72 hours after Day 0 and day 28 dosing
To characterize the pharmacokinetic parameter AUC0-t
Area under the concentration-time curve from 0 to the collection time t (AUC0-t)
Time frame: SAD: within 60 min before dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24, 48 and 72 hours after dosing; MAD: within 60 minutes before day 0 and day 28 dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24 ,48 and 72 hours after Day 0 and day 28 dosing
To characterize the pharmacokinetic parameter t1/2
Half-Life (t1/2)
Time frame: SAD: within 60 min before dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24, 48 and 72 hours after dosing; MAD: within 60 minutes before day 0 and day 28 dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24 ,48 and 72 hours after Day 0 and day 28 dosing
To characterize the pharmacokinetic parameter λz
Elimination rate constant (λz)
Time frame: SAD: within 60 min before dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24, 48 and 72 hours after dosing; MAD: within 60 minutes before day 0 and day 28 dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24 ,48 and 72 hours after Day 0 and day 28 dosing
To characterize the pharmacokinetic parameter CL/F
Oral clearance (CL/F)
Time frame: SAD: within 60 min before dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24, 48 and 72 hours after dosing; MAD: within 60 minutes before day 0 and day 28 dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24 ,48 and 72 hours after Day 0 and day 28 dosing
To characterize the pharmacokinetic parameter Vz/F
Volume of distribution in the terminal elimination period (Vz/F)
Time frame: SAD: within 60 min before dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24, 48 and 72 hours after dosing; MAD: within 60 minutes before day 0 and day 28 dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24 ,48 and 72 hours after Day 0 and day 28 dosing
To characterize the pharmacokinetic parameter AUC0-inf
Area under the concentration-time curve from 0 to infinity
Time frame: SAD: within 60 min before dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24, 48 and 72 hours after dosing; MAD: within 60 minutes before day 0 and day 28 dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24 ,48 and 72 hours after Day 0 and day 28 dosing
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2023 to primary completion in Mar 2025, 21 months.
Of 47 industry-sponsored phase 1 interventional studies under Hyperlipidemias, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's 21 months is above that.
Counting every sponsor, half of 54 studies reached it within 3 months; a quarter within 1 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Suzhou Ribo Life Science Co. Ltd. →